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INTRODUCTION
could induce resistance to irreversible EGFR inhibitors (11). IL-6/STAT3 signaling may be a potential 87 therapeutic target for enhancing the efficacy of EGFR-TKIs. Therefore, reversing EMT and decreasing 88 IL-6 signaling activation may be an effective way to improve the response to EGFR-TKI treatment. 89 Metformin is a widely used and well tolerated drug for diabetes and has arisen keen interest as a 90 potential anticancer agent ever since the report of the clinical evidence that the cancer risk and mortality 91 are reduced in diabetics receiving metformin (12). Metformin exerts remarkable antitumor properties in overcome TKI resistance by reversing EMT and inhibiting IL-6 signaling pathways. One recent study 98 reported that metformin in combination with gefitinib significantly enhanced the efficacy of targeted 99 therapy (17). However, the mechanism underlying this effect remains unclear. 100 Here we show that metformin in combination with gefitinib or erlotinib has a synergistic inhibitory 101 effect on the proliferation, migration and invasion of cell lines resistant to TKIs. The effect of metformin 102 against TKI resistance is attributed to its ability to reverse EMT and decrease IL-6 signaling activation. 103 In addition, this combinational therapy reduces tumor masses much more effectively than gefitinib or 104 metformin alone in a xenograft mouse model, and this synergistic interaction is associated with the 105 ability of metformin to decrease the activation of STAT3 and AKT and reverse EMT. We thus provide ~30 mm 3 within 5-7 days. The mice were then randomly assigned to four groups (eight mice/group) with 135 or without oral administration of 1mg/ml metformin, or 250 mg/L gefetinib, or both, in drinking water.
136
Tumor volume was calculated as (length × width 2 )/2 and measured twice a week (Fig. 5A ). The animals 137 were kept in individual ventilated cages in compliance with institutional guidelines. All animal protocols 138 were approved by the Ethics Committee of the Third Military Medical University. After 4 weeks, 139 tumor-bearing mice were sacrificed, and tumors were harvested, fixed with 4% paraformaldehyde and 140 embedded in paraffin. To assess survival, the animals were monitored for 90 days until being euthanized.
141
The distribution of survival percentages over time was estimated using the Kaplan-Meier method.
143
Statistical analysis 144 All data are presented as mean ± standard error of the mean (SEM). Statistical analyses were carried out 145 using the unpaired, two-tailed Student's t test and statistical significance was assumed at a value of p < 146 0.05. Kaplan-Meier curves were compared using the Log-rank test. 151 We first performed MTT assays to determine whether metformin could enhance the inhibitory effects of 152 TKIs on the growth of TKI-resistant lung cancer cell lines, PC-9GR and H1650-M3. PC-9 cells were 153 highly sensitive to gefitinib (Fig. 1A) , while PC-9GR cells were highly resistant to it (Fig. 1B) . 154 Treatment with 5 mM metformin resensitized PC-9GR to gefitinib ( in the current study, we next examined the expression of organic cation transporter 1 (OCT1), the 165 transporter required for uptake of metformin, in PC-9, PC-9GR, H1650, and H1650-M3 cells. Results
RESULTS
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Metformin resensitizes EGFR-TKI-resistant human lung cancer cells in vitro
166
showed that these cell lines expressed high levels of OCT-1, suggesting that metformin can be uptaken 167 by those cell lines (Supplementary Figure 3) . 168 To further determine whether metformin in combination with TKIs has a better inhibitory effect on 169 tumor cell invasion and migration than metformin or TKIs alone, we performed transwell assay and Metformin decreases IL-6 signaling activation in TKI-resistant lung cancer cell lines 196 To identify the molecular mechanisms of overcoming acquired TKI resistance by metformin, we next 197 examined the effect of metformin on IL-6 activation in TKI-resistant cell lines, which was reported to be 198 the key mechanism underlying TKI resistance and the promoter of the EMT process (10). We first Metformin overcomes IL-6-induced TKI resistance in TKI sensitive lung cancer cells 220 Given that the stimulation of TKI-sensitive cells by IL-6 could directly decrease erlotinib sensitivity (10), 221 we then investigated whether metformin could overcome IL-6-induced TKI resistance. It was found that 222 48-h culture in IL-6-containing medium was able to decrease the sensitivity of PC-9 cells to gefitinib. 223 Interestingly, metformin addition restored the sensitivity of PC-9 cells to gefitinib (Fig. 3A) . Metformin (Fig. 3B) . Taken together, these results suggest that IL-6 is sufficient to decrease gefitinib 231 cytotoxicity, which can be reverted by metformin. 232 Next, we examined EMT and IL-6 activation in PC-9 cells treated with IL-6 or IL-6 plus metformin.
233
IL-6 treatment induced EMT in those sensitive cells, as characterized by spindle-shaped morphology, the 234 loss of E-cadherin and the expression of EMT markers Vimentin and SNAIL ( Fig. 3C-E) . In addition, 235 exposure to IL-6 resulted in significant phosphorylation of its downstream molecules STAT3 and AKT, 236 but inhibited the activation of AMPK and ACC ( Fig. 3D and E) . Metformin significantly reverted EMT, was combined with a 4-fold reduced dose of doxorubicin that is not effective as a monotherapy (14). 317 Metformin inhibited the proliferation of NSCLC (25) and breast cancer cell lines (26) , and blocked 318 transformation in an inducible model system (27, 28). These reports, together with our findings that 319 metformin significantly enhances the effect of erlotinib and gefitinib on TKI-resistant cell lines in vitro 320 and in vivo, suggest that metformin has the promising potential to be used as a novel anti-cancer agent. 321 The dose of metformin we used in in vitro experiments is higher than that used in diabetic patients. In the current study, we found that metformin could inhibit IL-6 secretion, decrease IL-6 signaling 379 activation and reverse EMT. It was also reported that metformin could reverse TGFβ-induced EMT (15). absence of IL-6 (10 ng/ml) for 48 h, and then cellular invasiveness was assessed by the transwell assay. 
